{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-310054","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2022-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.407725+00:00","generated_at":"2026-06-21T00:39:45.430130+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"BioMarin adopts amended bylaws with DGCL alignment and universal proxy rule updates","bullets":["Board approved amended bylaws effective Dec 15, 2022, updating notice and meeting adjournment to align with DGCL.","Requires stockholders soliciting proxies to use a proxy card color other than white.","Amends procedural mechanics for stockholder nominations and proposals under SEC Rule 14a-19 (Universal Proxy Rules).","Includes administrative, modernizing, and clarifying changes to the bylaws."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-310054","json":"https://secwatch.observer/filing/0001193125-22-310054.json","markdown":"https://secwatch.observer/filing/0001193125-22-310054.md","text":"https://secwatch.observer/filing/0001193125-22-310054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312522310054/0001193125-22-310054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312522310054/d440213d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:39:45.430130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e7df7ab3b9e92ac043a31b9f89b38966eea94349","claim":"BIOMARIN PHARMACEUTICAL INC: Amended and restated bylaws to update provisions related to stockholder meetings, proxy rules, and other administrative changes (effective 2022-12-15).","evidence_excerpt":"On December 15, 2022, the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) approved and adopted the Company’s Amended and Restated Bylaws (as so amended, the “Amended Bylaws”), effective as of December 15, 2022.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312522310054/0001193125-22-310054-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-12-15"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}